An Open Label, Dose Ranging, Exploratory Study to Evaluate the Safety, Tolerability, Compliance, Mechanism of Action and Efficacy of QBECO Site Specific Immunomodulation for the Induction of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis

Trial Profile

An Open Label, Dose Ranging, Exploratory Study to Evaluate the Safety, Tolerability, Compliance, Mechanism of Action and Efficacy of QBECO Site Specific Immunomodulation for the Induction of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2017

At a glance

  • Drugs QBECO (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Qu Biologics
  • Most Recent Events

    • 02 Aug 2017 Results published in the Qu Biologics media release
    • 27 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 23 Dec 2015 Enrollment of a second group of participants into this clinical trial is expected to begin in third quarter 2016, according to a Qu Biologics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top